Tiger Brokers

BUZZ- Guggenheim raises PT on ANI Pharma after Alimera deal completion

Reuters
Sep 17, 2024

** Brokerage Guggenheim raises PT on ANI Pharmaceuticals

to $83 from $77, retains "buy" rating

** New PT represents a 47.7% upside to stock's last close

** Says, updating its model following the close of the Alimera acquisition

** On Monday, ANIP announced it completed its acquisition of Alimera Sciences , expanding its rare disease business

** Brokerage estimates FY24 product revenues of $34.4 mln for Alimera, including sales of $4.1 mln for the last ~2 weeks of Q3 2024, which will be recorded by ANIP

** Says deal to have positive impact on ANIP's outlook

** Average rating of 5 brokerages is equivalent to "buy"; median PT is $83

** Up to last close, stock up 1.9% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10